Drug updated on 11/9/2023

Dosage FormTablet (oral; 20 mg, 100 mg)
Drug ClassDiarylquinoline antimycobacterials
Ongoing and
Completed Studies


  • Indicated as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB).

Product Monograph / Prescribing Information

Document TitleYearSource
Sirturo (bedaquiline) Prescribing Information.2021Janssen Therapeutics, Titusville, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review2023International Journal of Mycobacteriology
Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis. 2023International Journal of Infectious Diseases (IJID)
Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment. 2023PLoS One
Bedaquiline's Safety Profile Monitoring in India: Considerations for Future - A Systematic review. 2023Current Drug Safety
Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. 2023Clinical Infectious Diseases
The Efficacy and Safety of Bedaquiline in the Treatment of Pulmonary Tuberculosis Patients: A Systematic Review and Meta-Analysis. 2023Antibiotics
Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.2022Brazilian Journal of Pulmonology
Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis. 2022Pharmacological research
Effectiveness of the Novel Anti-TB Bedaquiline against Drug-Resistant TB in Africa: A Systematic Review of the Literature. 2022Pathogens
Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. 2022JAC-Antimicrobial Resistance
Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.2021BMC Infectious Diseases
The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review. 2021Health SA
A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments. 2021Frontiers in Pharmacology
Cost-Effectiveness of Bedaquiline in Multidrug Resistant Tuberculosis: A Review. 2021The Open Public Health Journal
Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. 2020Clinical Infectious Diseases
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.2018The Lancet

Clinical Practice Guidelines